key: cord-0740846-qgxo9cr7
authors: Vanshylla, K.; Tober-Lau, P.; Gruell, H.; Muenn, F.; Eggeling, R.; Pfeifer, N.; Le, N. H.; Landgraf, I.; Kurth, F.; Sander, L. E.; Klein, F.
title: Durability of Omicron-neutralizing serum activity following mRNA booster immunization in elderly individuals
date: 2022-02-02
journal: nan
DOI: 10.1101/2022.02.02.22270302
sha: 51deaadacb5c0389a859bd76e79fee0530ca8a0a
doc_id: 740846
cord_uid: qgxo9cr7

Elderly individuals are at high risk for severe COVID-19. Due to modest vaccine responses compared to younger individuals and the time elapsed since prioritized vaccinations, the emerging immune-evasive Omicron variant of SARS-CoV-2 is a particular concern for the elderly. Here we longitudinally determined SARS-CoV-2-neutralizing serum activity against different variants in a cohort of 37 individuals with a median age of 82 years. Participants were followed for 10 months after an initial two-dose BNT162b2 vaccination and up to 4.5 months after a BNT162b2 booster. Detectable Omicron-neutralizing activity was nearly absent after two vaccinations but elicited in 89% of individuals by the booster immunization. Neutralizing titers against the Wu01, Delta, and Omicron variants showed similar post-boost declines and 81% of individuals maintained detectable activity against Omicron. Our study demonstrates the mRNA booster effectiveness in inducing anti-Omicron activity and provides critical information on vaccine response durability in the highly vulnerable elderly population.

Correspondence should be addressed to leif-erik.sander@charite.de and florian.klein@uk-koeln.de perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22270302 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Elderly individuals are at high risk for severe . Due to modest vaccine responses 39 compared to younger individuals and the time elapsed since prioritized vaccinations, the 40 emerging immune-evasive Omicron variant of SARS-CoV-2 is a particular concern for the 41 elderly. Here we longitudinally determined SARS-CoV-2-neutralizing serum activity against 42 different variants in a cohort of 37 individuals with a median age of 82 years. Participants were 43 followed for 10 months after an initial two-dose BNT162b2 vaccination and up to 4.5 months 44 after a BNT162b2 booster. Detectable Omicron-neutralizing activity was nearly absent after perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Advanced age is a critical risk factor for morbidity and mortality associated with and is therefore of particular concern for the elderly. 2 However, while booster immunizations 80 can elicit Omicron-neutralizing activity, 3 their immediate and long-term effects in highly aged Here, we longitudinally determined SARS-CoV-2-neutralizing serum activity in a prospective 85 cohort of 37 individuals with a median age of 82 years (range 76-96 years; appendix p 2). 4

Participants were followed for 10 months after an initial two-dose BNT162b2 vaccination and 87 up to 4·5 months after a single booster dose of BNT162b2. 50% geometric mean inhibitory 88 serum dilutions (GeoMean ID50s) against the Wu01 vaccine strain as well as the Delta and 89 Omicron variants were determined using a pseudovirus assay (appendix p 4). All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22270302 doi: medRxiv preprint

Waning Immune Humoral Response to BNT162b2

Covid-19 Vaccine over 6 Months

Omicron extensively but incompletely escapes

Pfizer BNT162b2 neutralization. Nature. 2021. perpetuity.preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint inThe copyright holder for this this version posted February 2, 2022. ; https://doi.org/10.1101/2022.02.02.22270302 doi: medRxiv preprint